What does this research mean for the field?

The absence of pertuzumab and T-DM1 from the Brazilian public health system may lead to over 342 preventable deaths annually among patients with high-risk HER2-positive early breast cancer. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

This study aims to assess the impact of treatment gaps in HER2-positive breast cancer care within the Brazilian public health system.

February 19, 2026Clinical Cancer Research

Abstract PS4-12-03: Access-her: assessing consequences of standard-of-care gaps in her2-positive breast cancer in the brazilian healthcare system

View Full Paper

Ask AI

Bookmark

Authors

AMAndré MattarHospital São Paulo FCFernanda Vitória Oliveira CavalcanteHospital Geral de Fortaleza CLC. La-ScalaAlpha Br Produtos Químicos (Brazil)

Discussion

Member takes

Implication

Retrospective modeling study estimates preventable deaths due to treatment gaps in HER2-positive breast cancer in Brazil, suggesting critical healthcare improvements.

Key Points

This study aims to assess the impact of treatment gaps in HER2-positive breast cancer care within the Brazilian public health system.
Conducted a retrospective modeling study using data from Brazil's national public health database (DATASUS).
Included women aged 18 years or older with stage II or III HER2-positive early breast cancer treated in 2023.
Modeled three treatment scenarios: current SUS standard care, adjuvant T-DM1, and neoadjuvant dual HER2 blockade with T-DM1.
Projected 744 deaths over seven years under current SUS Standard of Care scenario.
Scenario 2 projected 520 deaths, a 30% reduction in mortality.
Scenario 3 estimated 402 deaths, a 46% reduction in mortality compared to the SUS Standard of Care.

Cite This Study

Mattar et al. (2026) studied this question.

synapsesocial.com/papers/6996a85cecb39a600b3eef53 https://doi.org/10.1158/1557-3265.sabcs25-ps4-12-03

View Full Paper

Ask AI

Bookmark

Implication

Retrospective modeling study estimates preventable deaths due to treatment gaps in HER2-positive breast cancer in Brazil, suggesting critical healthcare improvements.

Abstract PS4-12-03: Access-her: assessing consequences of standard-of-care gaps in her2-positive breast cancer in the brazilian healthcare system

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS4-12-03: Access-her: assessing consequences of standard-of-care gaps in her2-positive breast cancer in the brazilian healthcare system

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider